Compare Citius Pharmaceuticals Inc (CTXR) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Shell PLC — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Shell PLC trades at $100.18 (market cap $284.34B). The key difference: Shell PLC is far larger — about 20876.7× Citius Pharmaceuticals Inc's market cap, and Shell PLC pays a 3.12% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Shell PLC for 90 Days on average.
| CTXR | SHEL | |
|---|---|---|
Market Cap | $13.62M | $284.34B |
Volume | 132,438 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $1.82 | $100.20 |
52-Week Low | $0.48 | $70.31 |
Typical Hold Time | 17 Days | 90 Days |
Enterprise Value | $3.79M | $326.04B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Shell (SHEL) trades at $100.2, up 3.46% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats in Q1 and Q2 2026. Fundamentally, the company maintains solid profitability with an 8.76% net margin and attractive valuation multiples, including a P/E of 11.08. Recent news highlights strategic expansions in LNG capacity and carbon capture projects, reinforcing long-term growth prospects.
The outlook for SHEL is positive, supported by analyst consensus favoring Buy ratings and a $102.53 price target. Key opportunities include LNG expansion and portfolio optimization, while risks involve energy price volatility and execution of large-scale projects. The stock presents a balanced risk-reward profile for investors seeking exposure to energy transition themes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
